Scribd Logo
Upload

Welcome to Scribd!

  • Critical Appraisal On Meta Analysis: Jecsons Medical Center

    Uploaded by

    maine
    23 views21 pages
    This meta-analysis evaluated the efficacy of SGLT2 inhibitors for preventing cardiovascular events in patients with type 2 diabetes. It found: 1) SGLT2 inhibitors showed benefit in preventing major adverse cardiac events and myocardial infarction, both fatal and non-fatal. 2) However, the results were precise but not statistically significant. 3) For the patient, an SGLT2 inhibitor could be considered for primary prevention of cardiovascular outcomes as there was a trend toward benefit, despite a lack of statistical significance.

    Original Description:

    Original Title

    META-ANALYSIS-Final

    Copyright

    © © All Rights Reserved

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    This meta-analysis evaluated the efficacy of SGLT2 inhibitors for preventing cardiovascular events in patients with type 2 diabetes. It found: 1) SGLT2 inhibitors showed benefit in preventing major adverse cardiac events and myocardial infarction, both fatal and non-fatal. 2) However, the results were precise but not statistically significant. 3) For the patient, an SGLT2 inhibitor could be considered for primary prevention of cardiovascular outcomes as there was a trend toward benefit, despite a lack of statistical significance.

    Copyright:

    © All Rights Reserved
    Flag for inappropriate content
    23 views21 pages

    Critical Appraisal On Meta Analysis: Jecsons Medical Center

    Uploaded by

    maine
    This meta-analysis evaluated the efficacy of SGLT2 inhibitors for preventing cardiovascular events in patients with type 2 diabetes. It found: 1) SGLT2 inhibitors showed benefit in preventing major adverse cardiac events and myocardial infarction, both fatal and non-fatal. 2) However, the results were precise but not statistically significant. 3) For the patient, an SGLT2 inhibitor could be considered for primary prevention of cardiovascular outcomes as there was a trend toward benefit, despite a lack of statistical significance.

    Copyright:

    © All Rights Reserved
    Flag for inappropriate content
    of 21

    CRITICAL APPRAISAL ON META ANALYSIS

    • JECSONS MEDICAL CENTER

    DECEMBER 5, 2020
    CASE:

    • A 50/F consulted due to headaches and nape pains. A previous smoker, nonn alcoholic
    beverage drinker. G2P2 with regular menstruation.
    • Family History:
    • (+) HCVD CAD, (+) DM, S/P Myocardial Infarction, (+) CKD V on HD
    • PE:
    • BMI of 24kg/m² BP: 140/100. Other systems unremarkable
    CASE:
    CASE:
    Clinical Question

    • Does Adding an SGLT2 inhibitor prevent a major Cardiovascular endpoint and/or


    CKD?
    OBJECTIVES

    • To critically appraise a Meta-Analysis on the efficacy of SGLT 2 Inhibitor for the


    prevention of Cardiovascular events in Patients with Type 2 Diabetes Mellitus.
    OUTLINE

    • APPRAISING DIRECTNESS
    • APPRAISING VALIDITY
    • Were the criteria for inclusion of studies
    appropriate?
    • Was the search for eligible studies
    thorough?
    • Was the validity of the included studies
    assessed?
    • Were the assessments of the studies
    reproducible?
    OUTLINE

    • APPRAISING THE RESULTS


    • What are the overall results of the
    review?
    • Were the results similar from the study
    to study?
    • How precise were the results?
    • ASSESSING APPLICABILITY
    • INDIVIDUALIZING THE RESULTS
    • SUMMARY
    APPRAISING THE DIRECTNESS
    APPRAISING THE VALIDITY
    Were the criteria for inclusion of studies appropriate?
    APPRAISING THE VALIDITY
    Was the search for eligible studies thorough?
    APPRAISING THE VALIDITY
    Was the validity of the included studies assessed?
    APPRAISING THE VALIDITY
    Were the assessments of the studies reproducible?
    APPRAISING THE RESULTS
    What are the overall results of the review?
    APPRAISING THE RESULTS
    Were the results similar from the study to study?
    APPRAISING THE RESULTS
    How precise were the results?

    • Results from the Meta Analysis Report showed benefit from prevention of Major
    Adverse Cardiac Events and Myocardial Infarction whether it is Fatal or Non-Fatal
    using SGLT2 Inhibitors.
    • However, results were precise but not statistically significant.
    ASSESSING APPLICABILITY
    Are the biologic issues affecting applicability?
    ASSESSING APPLICABILITY
    Are the socio-economic issues affecting applicability?

    • No significant socio-economic issues were cited on this Meta-Analysis Report.


    ASSESSING APPLICABILITY
    If the overall results of the overview are not directly applicable to your
    patient, are there credible subgroup analyzes that you could use?
    INDIVIDUALIZING THE RESULTS
    What is the implication of study findings on your individual patient?

    • For primary prevention of MACE, Cardiovascular Death & Fatal/Non-Fatal


    Myocardial Infarction, although there is no statistically significant benefit, there is still
    a trend towards benefit. Hence, we can still consider using SGLT2 Inhibitor for our
    case.
    INDIVIDUALIZING THE RESULTS
    Would you offer the treatment to your patient?

    • YES
    Thank you for listening!

    You might also like